SPECTRUM PHARMACEUTICALS, INC. (NASDAQ:SPPI) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

SPECTRUM PHARMACEUTICALS, INC. (NASDAQ:SPPI) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Story continues below

(d)Exhibits

Exhibit

No.

Description

99.1 Press Release, dated December17, 2017.


SPECTRUM PHARMACEUTICALS INC Exhibit
EX-99.1 2 d465506dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Spectrum Pharmaceuticals Announces Leadership Changes Joseph W. Turgeon Named President and CEO and Elected to the Board of Directors Thomas J. Riga Named Chief Operating Officer Stuart M. Krassner,…
To view the full exhibit click here

About SPECTRUM PHARMACEUTICALS, INC. (NASDAQ:SPPI)

Spectrum Pharmaceuticals, Inc. is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has approximately six approved oncology/hematology products that target different types of non-Hodgkin’s lymphoma (NHL), metastatic colorectal cancer, acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). It also has two drugs in late-stage development: SPI-2012, which is being developed for chemotherapy-induced neutropenia in patients with breast cancer, and EOQUIN, which is being developed for immediate intravesical instillation post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. It has a product portfolio consisting of both commercial-stage and development-stage products that address various cancer types. Its commercialized products include FUSILEV, FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ and EVOMELA. Its other products include SPI-2012, POZIOTINIB and EOQUIN.

An ad to help with our costs